Importantly, however, SPAG5, which is not a top driver in the TARGET cohort, implies a significant difference between the molecular landscape of the pathways and how they can be targeted in different AML age groups, which is already supported by current research (Shahzya Chaudhury, Caitríona O’Connor et al. 2018; Ma et al. 2018; Aung et al. 2021). The gene discussed is SPAG5; the disease is acute myeloid leukemia.